

LISTING OF CLAIMS:

1. (Currently Amended) A pharmaceutical aqueous suspension comprising:
 - a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;
 - b) a thickener;
 - c) a uniformly dispersed nucleation inhibitor, wherein said nucleation inhibitor reduces growth rate of said active ingredient compared to suspensions not containing a nucleation inhibitor and wherein said nucleation inhibitor is polyvinylpyrrolidone; and
 - d) at least one amino polycarboxylic acid compound;wherein the pharmaceutical aqueous suspension has a pH of about 3.7 to about 8; and wherein the amino polycarboxylic acid compound imparts improved pH and viscosity stability to the pharmaceutical aqueous suspension.
2. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the suspended solid particles are hydrophobic and the suspension further comprises a surfactant.
3. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns.
4. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the ~~suspension~~thickener comprises a blend of at least a structuring agent and a swelling agent ~~as the thickener.~~
5. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the active ingredient is substantially insoluble in an aqueous environment at room temperature.
6. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1; wherein the pharmaceutical aqueous suspension has a pH between about 3 and about 6 at room temperature.

7. (Cancelled)


8. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the pH of the pharmaceutical aqueous suspension remains within about 0.2 pH units for a period of at least about four weeks ~~starting from its complete formulation~~ when stored at a temperature of at least about 60°C.

9. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1; wherein the viscosity remains constant for at least about two weeks when stored at a temperature of at least about 60°C.

10. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the viscosity remains within a range of plus or minus about 25% of its initial value for a period of at least about 8 weeks when stored at a temperature of about 60°C.

11. (Currently Amended) A pharmaceutical aqueous suspension according to claim 1, wherein the at least one amino polycarboxylic acid compound is a compound ~~according to~~ selected from the group consisting of:

formula (I) and pharmaceutically acceptable salts thereof:




wherein R₁ and R₂, independently of one another, are hydrogen, hydroxy-terminated C₁-C₄ alkylene, carboxylic-terminated C₁-C₄ alkylene or N-[R₃OOH]_m;

~~and~~ wherein R₃, R₄, R₅ and R₆ ~~are~~ are, independently of one another, are C₁-C₄ alkylene; and

wherein m is 1 or 2;

~~or~~ formula (II)



wherein R₇, R₈ and R₉, independently of one another, are hydrogen, C₁-C₄ alkyl, carboxylic-terminated C₁-C₄ alkylene or hydroxy-terminated C₁-C₄ alkylene; and

pharmaceutically acceptable salts of formula (I) or (II).

12. (Currently Amended) A pharmaceutical aqueous suspension according to claim 11, wherein the at least one amino polycarboxylic acid compound is represented by formula (I) and wherein R₁, R₂ and R₃ are ethylene.

13. (Currently Amended) A suspension according to claim 1, wherein the at least one amino polycarboxylic acid compound is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid, dihydroxyethylethylenediaminediacetic acid, 1,3-propanediaminetetraacetic acid, diethylenetriaminepentaacetic acid, triethylenetetraminehexaacetic acid, iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, ~~and~~ salts thereof, and mixtures thereof.

14. (Currently Amended) A suspension according to claim 1, wherein the at least one amino polycarboxylic acid compound is selected from ethylenediaminetetraacetic acid, salts thereof and mixtures thereof.

15. (Currently Amended) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is disodium ethylenediaminetetraacetate.

16. (Currently Amended) A suspension according to claim 11, wherein the active ingredient is an anti-histamine or an analgesic.

17. (Currently Amended) A suspension according to claim 14, wherein the active ingredient is loratadine.

18. (Withdrawn) A suspension according to claim 16 wherein the active ingredient is acetaminophen or ibuprofen.

19. (Currently Amended) A pharmaceutical aqueous suspension comprising:

a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;

b) a blended thickening component comprising xanthan gum and pre-gelatinized starch;

c) at least one amino polycarboxylic acid compound; and

d) polyvinylpyrrolidone;

wherein the pharmaceutical aqueous suspension has a pH of about 3.7 to 8; and

wherein the amino polycarboxylic acid compound imparts improved pH and viscosity stability to the pharmaceutical aqueous suspension.

20. (Cancelled)

21. (Currently Amended) A suspension according to claim 19, further comprising a surfactant.

22. (Currently Amended) A pharmaceutical aqueous suspension comprising:

a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient selected from the group consisting of fexofenadine, loratadine, desloratadine, terfenadine, astemizole, norastemizole, cetirizine, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof,

wherein the pharmaceutical aqueous suspension comprises polyvinylpyrrolidone and has a pH of about 3.7 to about 8; ~~and~~

wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns after about 4 weeks at about 60°C; and

wherein the amino polycarboxylic acid compound imparts improved pH and viscosity stability to the pharmaceutical aqueous suspension.

23. (Currently Amended) A pharmaceutical aqueous suspension of claim 1, wherein said active ingredient is loratadine.

24. (Currently Amended) A pharmaceutical aqueous suspension of claim 19, wherein said active ingredient is loratadine.

25. (Currently Amended) A pharmaceutical aqueous suspension of claim 22, wherein said active ingredient is loratadine.